ARCH Venture Fund IX, L.P. - Dec 31, 2024 SCHEDULE 13G/A Report for Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share (LYEL)

Filing Manager
ARCH Venture Fund IX, L.P.
Reporting Manager
Robert Nelsen
Security
Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share
Symbol
LYEL
Shares outstanding
279M shares
Disclosed Ownership
36.6M shares
Ownership
13.1%
Form type
SCHEDULE 13G/A
Date filed
2/14/2025, 04:55 PM
Date of event
Dec 31, 2024
SEC
View on sec.gov

Reporting Managers (8)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
ARCH Venture Fund IX, L.P. 13% 36.4M 0 36.4M ARCH Venture Partners IX, L.P. its General Partner
ARCH Venture Fund IX Overage, L.P. 13% 36.4M 0 36.4M ARCH Venture Partners IX Overage, L.P. its General Partner
ARCH Venture Partners IX, L.P. 13% 36.4M 0 36.4M ARCH Venture Partners IX, LLC its General Partner
ARCH Venture Partners IX Overage, L.P. 13% 36.4M 0 36.4M ARCH Venture Partners IX, LLC its General Partner
ARCH Venture Partners IX, LLC 13% 36.4M 0 36.4M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Keith Crandell 13% 36.4M 0 36.4M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Clinton Bybee 13% 36.4M 0 36.4M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Clinton Bybee
Robert Nelsen 13.1% 36.6M 185K 36.4M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Robert Nelsen